Literature DB >> 29672443

Belatacept and Autoimmune Adverse Events.

Simon Ville1, Diego Cantarovich1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29672443      PMCID: PMC7228644          DOI: 10.1097/TP.0000000000002247

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  5 in total

Review 1.  Psoriatic skin lesions induced by abatacept: Case report and review of the published work.

Authors:  Ikuko Ueda-Hayakawa; Chuyen Nguyen Thi Hong; Yoko Ueki; Naotomo Kambe; Hiroyuki Okamoto
Journal:  J Dermatol       Date:  2016-08-20       Impact factor: 4.005

2.  Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.

Authors:  Josh Levitsky; Joshua Miller; Xuemei Huang; Dhivya Chandrasekaran; Li Chen; James M Mathew
Journal:  Transplantation       Date:  2013-10-27       Impact factor: 4.939

3.  High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.

Authors:  S M Krummey; J A Cheeseman; J A Conger; P S Jang; A K Mehta; A D Kirk; C P Larsen; M L Ford
Journal:  Am J Transplant       Date:  2014-03       Impact factor: 8.086

4.  Stricturing Crohn's disease-like colitis in a patient treated with belatacept.

Authors:  Anne Bozon; Guillaume Jeantet; Benjamin Rivière; Natalie Funakoshi; Gaspard Dufour; Roman Combes; Jean-Christophe Valats; Sylvie Delmas; Jean Emmanuel Serre; Michael Bismuth; Jeanne Ramos; Moglie Le Quintrec; Pierre Blanc; Guillaume Pineton de Chambrun
Journal:  World J Gastroenterol       Date:  2017-12-28       Impact factor: 5.742

Review 5.  Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?

Authors:  Simon Ville; Nicolas Poirier; Gilles Blancho; Bernard Vanhove
Journal:  Front Immunol       Date:  2015-08-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.